541 related articles for article (PubMed ID: 25096574)
1. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
2. Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET.
Liu Q; Leber B; Andrews DW
Cell Cycle; 2012 Oct; 11(19):3536-42. PubMed ID: 22895112
[TBL] [Abstract][Full Text] [Related]
3. BH3 domains other than Bim and Bid can directly activate Bax/Bak.
Du H; Wolf J; Schafer B; Moldoveanu T; Chipuk JE; Kuwana T
J Biol Chem; 2011 Jan; 286(1):491-501. PubMed ID: 21041309
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A
J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714
[TBL] [Abstract][Full Text] [Related]
5. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Stauffer SR
Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
[TBL] [Abstract][Full Text] [Related]
7. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets.
Kodama T; Takehara T; Hikita H; Shimizu S; Shigekawa M; Li W; Miyagi T; Hosui A; Tatsumi T; Ishida H; Kanto T; Hiramatsu N; Yin XM; Hayashi N
J Biol Chem; 2011 Apr; 286(16):13905-13. PubMed ID: 21367852
[TBL] [Abstract][Full Text] [Related]
8. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
9. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
10. BH3-only protein bid participates in the Bcl-2 network in healthy liver cells.
Hikita H; Takehara T; Kodama T; Shimizu S; Hosui A; Miyagi T; Tatsumi T; Ishida H; Ohkawa K; Li W; Kanto T; Hiramatsu N; Hennighausen L; Yin XM; Hayashi N
Hepatology; 2009 Dec; 50(6):1972-80. PubMed ID: 19839062
[TBL] [Abstract][Full Text] [Related]
11. Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax.
Shamas-Din A; Bindner S; Chi X; Leber B; Andrews DW; Fradin C
Biochem J; 2015 May; 467(3):495-505. PubMed ID: 25714678
[TBL] [Abstract][Full Text] [Related]
12. Examining BCL-2 family function with large unilamellar vesicles.
Asciolla JJ; Renault TT; Chipuk JE
J Vis Exp; 2012 Oct; (68):. PubMed ID: 23070252
[TBL] [Abstract][Full Text] [Related]
13. Mimicking the BH3 domain to kill cancer cells.
Ni Chonghaile T; Letai A
Oncogene; 2008 Dec; 27 Suppl 1(0 1):S149-57. PubMed ID: 19641500
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
[TBL] [Abstract][Full Text] [Related]
15. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.
Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP
Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698
[TBL] [Abstract][Full Text] [Related]
16. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
Certo M; Del Gaizo Moore V; Nishino M; Wei G; Korsmeyer S; Armstrong SA; Letai A
Cancer Cell; 2006 May; 9(5):351-65. PubMed ID: 16697956
[TBL] [Abstract][Full Text] [Related]
17. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Del Gaizo Moore V; Schlis KD; Sallan SE; Armstrong SA; Letai A
Blood; 2008 Feb; 111(4):2300-9. PubMed ID: 18056841
[TBL] [Abstract][Full Text] [Related]
18. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.
Kuwana T; Bouchier-Hayes L; Chipuk JE; Bonzon C; Sullivan BA; Green DR; Newmeyer DD
Mol Cell; 2005 Feb; 17(4):525-35. PubMed ID: 15721256
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for Bcl-2 homology 3 domain recognition in the Bcl-2 protein family: identification of conserved hot spot interactions.
Moroy G; Martin E; Dejaegere A; Stote RH
J Biol Chem; 2009 Jun; 284(26):17499-511. PubMed ID: 19293158
[TBL] [Abstract][Full Text] [Related]
20. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.
Buron N; Porceddu M; Brabant M; Desgué D; Racoeur C; Lassalle M; Péchoux C; Rustin P; Jacotot E; Borgne-Sanchez A
PLoS One; 2010 Mar; 5(3):e9924. PubMed ID: 20360986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
